Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company specializing in endocrine diseases and tumors, has announced its participation in three major investor conferences this December. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York, and both the Citi Global Healthcare Conference and Evercore 7th Annual HealthCONx Conference in Miami. Management will conduct fireside chats on December 3rd at 7:30 AM ET (Evercore), December 4th at 9:30 AM ET (Citi), and December 5th at 1:00 PM ET (Piper Sandler). Live and archived webcasts will be available on the company's website.
Crinetics Pharmaceuticals (Nasdaq: CRNX), un'azienda farmaceutica in fase clinica specializzata in malattie endocrine e tumori, ha annunciato la sua partecipazione a tre importanti conferenze per investitori questo dicembre. L'azienda presenterà alla 36ª Conferenza Annuale sulla Sanità di Piper Sandler a New York, e sia alla Conferenza Globale sulla Sanità di Citi che alla 7ª Conferenza Annuale HealthCONx di Evercore a Miami. La direzione condurrà conversazioni informali il 3 dicembre alle 7:30 AM ET (Evercore), il 4 dicembre alle 9:30 AM ET (Citi), e il 5 dicembre alle 1:00 PM ET (Piper Sandler). Saranno disponibili webcast dal vivo e registrati sul sito web dell'azienda.
Crinetics Pharmaceuticals (Nasdaq: CRNX), una compañía farmacéutica en etapa clínica especializada en enfermedades tumorales y endocrinas, ha anunciado su participación en tres importantes conferencias de inversores este diciembre. La compañía se presentará en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York, así como en la Citi Global Healthcare Conference y la 7ª Conferencia Anual HealthCONx de Evercore en Miami. La gerencia realizará charlas informales el 3 de diciembre a las 7:30 AM ET (Evercore), el 4 de diciembre a las 9:30 AM ET (Citi), y el 5 de diciembre a la 1:00 PM ET (Piper Sandler). Habrá webcasts en vivo y grabados disponibles en el sitio web de la compañía.
크리네틱스 제약 (Nasdaq: CRNX)는 내분비 질환 및 종양을 전문으로 하는 임상 단계 제약 회사로, 이번 12월에 세 개의 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 뉴욕에서 열리는 파이퍼 샌들러 제36회 연례 헬스케어 회의와 마이애미에서 열리는 시티 글로벌 헬스 케어 컨퍼런스, 에버코어 제7회 연례 헬스컨스 회의에 참석합니다. 경영진은 12월 3일 오전 7시 30분 ET(에버코어), 12월 4일 오전 9시 30분 ET(시티), 12월 5일 오후 1시 ET(파이퍼 샌들러)에 대화 형식의 발표를 진행할 예정입니다. 회사 웹사이트에서 실시간 및 녹화된 웹캐스트를 확인할 수 있습니다.
Crinetics Pharmaceuticals (Nasdaq: CRNX), une entreprise pharmaceutique en phase clinique spécialisée dans les maladies endocriniennes et les tumeurs, a annoncé sa participation à trois grandes conférences d'investisseurs ce décembre. L'entreprise présentera à la 36e Conférence Annuelle de Santé de Piper Sandler à New York, ainsi qu'à la Conférence Mondiale sur la Santé de Citi et à la 7e Conférence Annuelle HealthCONx d'Evercore à Miami. La direction participera à des discussions informelles le 3 décembre à 7h30 ET (Evercore), le 4 décembre à 9h30 ET (Citi) et le 5 décembre à 13h00 ET (Piper Sandler). Des webcasts en direct et archivés seront disponibles sur le site web de l'entreprise.
Crinetics Pharmaceuticals (Nasdaq: CRNX), ein klinisches Pharmaunternehmen, das sich auf endokrine Erkrankungen und Tumore spezialisiert hat, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im Dezember angekündigt. Das Unternehmen wird auf der 36. jährlichen Gesundheitskonferenz von Piper Sandler in New York sowie auf der Citi Global Healthcare Conference und der 7. jährlichen HealthCONx-Konferenz von Evercore in Miami präsentieren. Die Geschäftsführung wird am 3. Dezember um 7:30 Uhr ET (Evercore), am 4. Dezember um 9:30 Uhr ET (Citi) und am 5. Dezember um 13:00 Uhr ET (Piper Sandler) informelle Gespräche führen. Live- und aufgezeichnete Webcasts werden auf der Website des Unternehmens verfügbar sein.
- None.
- None.
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in three upcoming investment bank conferences. The Piper Sandler 36th Annual Healthcare Conference is being held in New York, NY, and both the Citi Global Healthcare Conference and the Evercore 7th Annual HealthCONx Conference are taking place in Miami, FL.
Evercore 7th Annual HealthCONx Conference
Fireside chat on Tuesday, December 3, 2024 at 7:30 a.m. Eastern Time
Webcast link HERE
Citi Global Healthcare Conference
Fireside chat on Wednesday, December 4, 2024 at 9:30 a.m. Eastern Time
Webcast link HERE
Piper Sandler 36th Annual Healthcare Conference
Fireside chat on Thursday, December 5, 2024 at 1:00 p.m. Eastern Time
Webcast link HERE
The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.
If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When is Crinetics Pharmaceuticals (CRNX) presenting at the Evercore HealthCONx Conference 2024?
Which investor conferences is Crinetics Pharmaceuticals (CRNX) attending in December 2024?
Where can investors watch Crinetics Pharmaceuticals (CRNX) conference presentations?
Which cities are hosting Crinetics Pharmaceuticals (CRNX) December 2024 investor conferences?
